Physician profile
Masaru Nishiaoki
NPI 1871026831
$6,080.19
in general payments reported to CMS, 2019-2025
21 companies · $1,068 in 2025
The $1,068 reported for 2025 was more than what 89% of Addiction Medicine (Family Medicine) providers received nationally (typical 2025 total: $143).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $60.60 · 2022: $2,092 · 2023: $1,510 · 2024: $1,350 · 2025: $1,068.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,928.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,927.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,133.84 | 2022-2025 | Invega Sustenna, Spravato |
| Abbvie INC. | $1,047.42 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $904.79 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $536.53 | 2022-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Supernus Pharmaceuticals, INC. | $425.54 | 2024-2025 | Qelbree |
| Axsome Therapeutics, INC. | $394.07 | 2023-2024 | Auvelity |
| Neurocrine Biosciences, INC. | $354.85 | 2022-2025 | Ingrezza |
| Alkermes, INC. | $343.46 | 2021-2025 | Lybalvi, Aristada |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $136.72 | 2022-2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $135.19 | 2025 | Cobenfy |
| Corium, LLC | $132.64 | 2022-2025 | Azstarys |
| Neos Therapeutics, Lp | $114.35 | 2022-2025 | Adzenys Xr-Odt |
| Braeburn INC. | $97.10 | 2023-2025 | Brixadi |
| Sunovion Pharmaceuticals INC. | $79.47 | 2022 | |
| Vanda Pharmaceuticals INC. | $66.74 | 2022-2025 | Fanapt |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $41.06 | 2022-2023 | Trintellix |
| Lundbeck LLC | $37.70 | 2023-2024 | Rexulti |
| Almatica Pharma LLC | $37.13 | 2022 | |
| Tris Pharma INC | $21.21 | 2025 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $20.57 | 2024 | |
| Indivior INC. | $19.81 | 2025 | Sublocade |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Masaru Nishiaoki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.